Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Midazolam · Midazolam In 0.9% Sodium Chloride, Nayzilam

Small molecule · Agonist of GABA A receptor (GABRA1) · developed by Mmt

Approved FDA, Sep 2018

1 Registered trials

What is Midazolam?

Midazolam is a benzodiazepine that potentiates GABAergic neurotransmission by binding at the benzodiazepine site of the GABA A receptor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Midazolam In 0.9% Sodium Chloride, Nayzilam, Seizalam, MDZ, USL-261
Drug type: Small molecule
Targets: GABA A receptor (GABRA1)
Mechanism: Agonist of GABA A receptor (GABRA1)
Pathways: GABAergic neurotransmission
Therapy area: Neurology
Developer: Mmt
In trials of: AGMB
FDA status: Approved as Midazolam In 0.9% Sodium Chloride, Nayzilam, Seizalam (September 14, 2018), NDA209566 · FDA label
UNII: R60L0SM5BC

✅ FDA-approved uses

Acute treatment of seizure clusters or acute repetitive seizures in patients with epilepsy (Nayzilam)

From the indications section of the FDA label (version of Jan 19, 2023). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05937386	Phase 1	Healthy Volunteers	Completed	AGMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

Other drugs acting on GABRA1

Remimazolam FDA approved Zuranolone FDA approved

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z